Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 6, 1996, Pages 1346-1351

  Deminie, Carol A ^a   Bechtold, Clifford M ^a   Stock, David ^a   Alam, Masud ^a   Djang, Fred ^a   Balch, Alfred H ^a   Chou, Ting Chao ^b   Prichard, Mark ^c   Colonno, Richard J ^a   Lin, Pin Fang ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BMS 186318; DIDANOSINE; INDINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TELINAVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 8944263470     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.6.1346     Document Type: Article

References (48)

1. Bechtold, C. M., A. K. Patick, M. Alam, J. Greytok, J. A. Tino, P. Chen, E. Gordon, S. Ahmad, J. C. Barrish, R. Zahler, P.-F. Lin, and R. J. Colonno. 1995. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother. 39:374-379.
2. Bianchi, V., S. Borella, F. Calderazzo, P. Ferraro, L. Chieco-Bianchi, and P. Reichard. 1994. Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs, possible application in AIDS treatment Proc. Natl. Acad. Sci USA 91:8403-8407.
3. Caliendo, A. M., and M. S. Hirsch. 1994. Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect. Dis. 18:516-524.
4. Chong, K.-T., P. J. Pangano, and R. R. Hinshaw. 1994. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother. 38:288-293
5. Chou, T.-C., and P. Talalay. 1984. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul. 22:27-55.
6. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature (London) 374:569-571.
7. Cooley, T. P., L. M. Kunches, C. A. Saunders, J. K. Ritter, C. J. Perkins, C. McLaren, R. P. McCaffrey, and H. A. Liebman. 1990. Once-daily administration of 2′,3′-dideoxyinosine (ddI) m patients with the acquired immunodeficiency syndrome or AIDS-related complex: results of a phase 1 trial. N. Engl. J. Med. 322:1340-1345
8. Craig, J. C., I. B. Duncan, L. Whittaker, and N. A. Roberts. 1990. Antiviral synergy between inhibitors of HIV proteinase and reverse transcriptase. Antivir. Chem. Chemother. 4:161-166.
9. Craig, J. C., C. Grief, J. S. Mills, D. Hockley, I. B. Duncan, and N. A. Roberts. 1991. Effects of a specific inhibitor of HIV proteinase (Ro 31-8959) on virus maturation in a chronically infected promonocytic cell line U1. Antiviral Chem. Chemother. 2:181-186.
10. Craig, J. C., L. Whittaker, I. B. Duncan, and N. A. Roberts. 1994. In vitro anti-HIV and cytotoxicological evaluation of the triple combination. AZT and ddC with HIV proteinase inhibitor saquinavir (Ro 31-8959). Antivir. Chem Chemother. 5:380-386.
11. DeClercq, E. 1994. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:155-169.
12. Eron, J. J., Jr., V. A. Johnson, D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1992. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro Antimicrob. Agents Chemother. 36:1559-1562.
13. Fischl, M. A., D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, D. King, and The A.C.W. Group. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317:185-191
14. Fischl, M. A., K. Stanley, A. C. Collier, J. M. Arduino, D. S. Stein, J. E. Feinberg, J. D. Allan, J. C. Goldsmith, W. G. Powderly, and The NACT Group. 1995. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann. Intern. Med. 122:24-32.
15. Fitzgibbon, J. E., R. E. Howell, C. A. Harberzettl, S. J. Sperber, D. J. Gocke, and D. T. Dublin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine Antimicrob Agents Chemother. 36:153-157.
16. Gao, W., D. G. Johns, and H. Mitsuya. 1994. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleotides Mol. Pharmacol 46:767-772.
17. Gao, W.-Y., T. Shirasaka, D. G. Johns, S. Broder, and H. Mitsuya. 1993 Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Med. Chem. 36:1221-1229.
18. Getman, D. P., G. A. DeCrescenzo, R. M. Heintz, K. L. Reed, J. J. Talley, M. L. Bryant, M. Clare, K. A. Houseman, J. J. Marr, R. A. Mueller, M. L. Vazquez, H.-S. Shieh, W. C. Stallings, and R. A. Stegeman. 1993. Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-hydroxyethyl-urea isostere. J. Med. Chem. 36:288-291.
19. Hammer, S. M., H. A. Kessler, and M. S. Saag. 1994. Issues m combination antiviral therapy: a review. J. Acquired Immune Defic. Syndr. 7:S24-S37.
20. Hartshorn, K. L., M. W. Vogt, T.-C. Chou, R. S. Blumberg, R. Byington, R. T. Schooley, and M. S. Hirsch. 1987. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob. Agents Chemother. 31:168-172.
21. Hitchcock, M. J. M. 1991. 2′,3′-Didehydro-2′,3′-dideoxythymidine (d4T), an anti-HIV agent. Antivir. Chem. Chemother. 2:125-132
22. Johnson, V. A., M. A. Barlow, D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1990 Three-drug Synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha. J. Infect. Dis. 161:1059-1067.
23. Johnson, V. A., D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1992. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-alpha against zidovudine-sensitive or -resistant HIV-1 in vitro. J. Infect. Dis. 166:1143-1146.
24. Johnson, V. A., D. P. Merrill, J. A. Videler, T.-C. Chou, R. E. Byington, J. J. Eron, R. T. D'Aquila, and M. S. Hirsch. 1991. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect Dis. 164:646-655.
25. Kageyama, S., J. N. Weinstein, T. Shirasaka, D. J. Kempf, D. W. Norbeck, J. J. Plattner, J. Erikson, and H. Mitsuya. 1992. In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob. Agents Chemother 36:926-933.
26. Karlsson, A., P. Reichard, and F. Eckstein. 1989. Hydroxyurea increases the phosphorylation of 3′-fluorothymidine and 3′-azidothymidine in CEM cells. Eur J. Biochem. 186:689-694
27. Kempf, D. J., L. Codacovi, X. C. Wang, W. E. Kohlbrenner, N. E. Wideburg, A. Saldivar, S. Vasavanonda, K. C. Marsh, P. Bryant, H. L. Sham, B. E. Green, D. A. Betebenner, J. Erikson, and D. W. Nurbeck. 1993. Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J. Med. Chem. 36:320-330.
28. Kozal, M. J., and T. C. Merigan. 1993. HIV resistance to dideoxynucleoside inhibitors (mini review). Infect. Dis. Clin. Prac. 2:247-253.
29. Lambert, D. M., H. Bartus, A. V. Fernandez, C. Bratby-Anders, J. J. Leary, G. B. Dreyer, B. W. Metcalf, and J. S. R. Petteway. 1993. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection. Antivir. Res. 21:327-342
30. Lambert, J. S., M. Seidlin, R. C. Reichman, C. S. Plank, M. Laverty, G. D. Morse, C. Knupp, C. McLaren, C. Pettinelli, F. T. Valentine, and R. Dolin. 1990. 2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase I trial. N. Engl. J Med. 322:1333-1340.
31. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734
32. Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature (London) 365:451-453.
33. Lin, P.-F., H. Samanta, R. E. Rose, A. K. Patick, J. Trimble, C. M. Bechtold, D. R. Revie, N. C. Khan, M. E. Federici, H. Li, A. Lee, R. E. Anderson, and R. J. Colonno. 1994. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates obtained from patients on prolonged stavudine therapy. J. Infect. Dis. 170:1157-1164.
34. Malley, D. S., J. M. Grange, F. Hamedi-Sangsari, and J. R. Vila. 1994. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds. Lancet 343:1292.
35. Merigan, T. C., G. Skowron, S. A. Bozette, D. Richman, R. Uttamchandani, M. A. Fischl, R. T. Schooley, M. S. Hirsch, W. Soo, C. Pettinelli, H. Schaumburg, The ddC Study Group, and The ACTG Group. 1989. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HTV) infections. A phase I and II study. Ann. Intern. Med. 110:189-194.
36. Meyerhans, A., J. Vartanian, C. Hultgren, U. Plikat, A. Karlsson, L. Wang, S. Eriksson, and S. Wain-Hobson. 1994. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68:535-540.
37. Moulding, T., A. K. Dutt, and L. B. Reichman. 1995. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann. Intern Med. 122:951-954.
38. Pagano, P. J., and K.-T. Chong. 1995. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delaviridine (U-90152) with protease inhibitor U-75875 or interferon-alpha. J. Infect. Dis. 171:61-67.
39. Prichard, M. N., K. R. Aseltine, and C. Shipman, Jr. 1992. MacSynergy II version 1.0 user's manual University of Michigan, Ann Arbor, Mich.
40. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993 Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
41. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents Antimicrob. Agents Chemother. 37: 1207-1213.
42. Roberts, N. A., J. A. Martin, D. Kinchington, A. V. Broadhurst, J. C. Craig, I. B. Duncan, S. A. Galpin, B. K. Handa, J. Kay, A. Krohn, R. W. Lambert, J. H. Merrett, J. S. Millis, K. E. B. Parkes, S. Redshaw, A. J. Ritchie, D. L. Taylor, G. J. Thomas, and P. J. Machin. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248:358-361.
43. Sorenson, A. M., C. Nielsen, L. R. Mathiesen, J. O. Nielsen, and J. S. Hansen. 1993 Evaluation of the combination effect of different antiviral compounds against HIV in vitro Scand. J. Infect Dis. 25:365-371.
44. Taylor, D. L., T. M. Brennan, C. G. Bridges, M. S. Kang, and A. S. Tyms. 1995. Synergistic inhibition of human immunodeficiency virus type 1 in vitro by 6-0-butanoylcastanospermine (MDL 28 574) m combination with inhibitors of the virus-encoded reverse transcriptase and proteinase. Antiviral Chem Chemother. 6:143-152.
45. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
46. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahey, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524: an orally bioavailable HIV-1 protease inhibitor. Proc. Natl. Acad Sci. USA 91:4096-4100.
47. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst 81:577-586.
48. Yerly, S., L. Kaiser, C. Baumberger, B. Hirschel, and L. H. Perrin. 1995 Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine. J AIDS Hum. Retroviruses 8:358-364.